Ascendia

  MARKET NEWS

Ocular Therapeutix Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs & Expansion of IP Portfolio for Sublingual Film
Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received US FDA Fast Track Designation for the Treatment of Extensive Stage Small Cell Lung Cancer & Extrapulmonary Neuroendocrine Cancers
Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed
Zevra Therapeutics Announces Interim Data From Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

  FEATURED EDITORIAL

  COMPANY PROFILE

PharmaCircle is a leading provider of authoritative information, global insight, and expert analysis on the pharmaceutical, biotech, drug delivery technology and device, and animal health industries. PharmaCircle’s premier database tracks drugs, biologics and combination products in all stages of development, connecting pipeline and product information with formulation and component details.  The database delivers seamless integration of scientific, clinical, safety, regulatory, manufacturing and commercial information, and detailed analyses on over 8,500 drug delivery technologies and delivery devices. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Sharp Acquires Berkshire Sterile Manufacturing

Sharp Acquires Berkshire Sterile Manufacturing

Sharp recently announced the acquisition of Berkshire Sterile Manufacturing (BSM), a Massachusetts-based fill finish contract development and manufacturing organization (CDMO) for….

Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Use in Preclinical & Clinical Drug Development

Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Use in Preclinical & Clinical Drug Development

Range of highly selective anti-idiotypic antibodies now includes six antibodies specific to dupilumab and its biosimilars for bioanalysis and drug monitoring….

Advent International & Warburg Pincus Complete Acquisition of Baxter’s BioPharma Solutions Business

Advent International & Warburg Pincus Complete Acquisition of Baxter’s BioPharma Solutions Business

Advent International, one of the largest and most experienced global private equity investors, and Warburg Pincus, a leading global growth investor, recently announced the completion of their previously announced acquisition of Baxter International Inc.’s BioPharma Solutions (BPS) business….

Evonik Strengthens Portfolio of Nanoparticle Technologies & Services for Parenteral Drug Delivery

Evonik Strengthens Portfolio of Nanoparticle Technologies & Services for Parenteral Drug Delivery

Evonik is strengthening its platform of parenteral drug delivery solutions with three new standard PLA-PEG di-block copolymers and a new nanoparticle formulation service using….

  WHITEPAPERS & WEBINARS

WEBINAR - Impact of Process Re-design on Sustainability in Pharmaceutical Small Molecule Manufacturing

WEBINAR - Impact of Process Re-design on Sustainability in Pharmaceutical Small Molecule Manufacturing

Join us for an upcoming webinar that delves into a crucial issue in the pharmaceutical industry. Recent research has revealed a surprising fact: the pharmaceutical sector has a larger carbon footprint than even the automotive industry, especially when we consider the entire supply chain’s impact on

WEBINAR - Beyond the Lab: Unleashing the Potential of In Silico Modeling in Drug Product Formulation

WEBINAR - Beyond the Lab: Unleashing the Potential of In Silico Modeling in Drug Product Formulation

In this webinar you will learn how digital chemistry tools facilitate rapid screening of formulation parameters, aiding in the identification of optimal drug delivery systems, excipient selection, and dosage forms….

  WHITEPAPERS & WEBINARS

WHITEPAPER - The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

WHITEPAPER - The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

Protein viscosity is one of the major obstacles in preparing highly concentrated protein formulations suitable for subcutaneous (subQ) injection. SubQ application of highly concentrated protein formulations enables a higher patient convenience and might thus lead to reduction in health costs. …

WHITEPAPER - Streamline Early-Stage Development to Reach the Clinic Faster

WHITEPAPER - Streamline Early-Stage Development to Reach the Clinic Faster

Early-stage development is critical to shortening your product’s timelines while establishing a solid foundation for clinical trials. In this insightful article from Dr. Srinivasan Shanmugam, Adare’s Executive Director of Pharmaceutical Sciences, learn what’s needed to make your product’s early-stage development …

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

Owing its convenience, oral administration is patients’ preferred route of delivery for therapeutic molecules. However, most New Chemical Entities (NCE) exhibit physico-chemical properties limiting their absorption in the gastro-intestinal (GI) tract. Indeed, according to Pharmacircle data from March 2022, almost …

WHITEPAPER - Effect of Excipient Choices on Topical Formulations & Manufacturing Processes

WHITEPAPER - Effect of Excipient Choices on Topical Formulations & Manufacturing Processes

In this whitepaper, we review the effect of excipient choice on the process of manufacturing topical products. The effect of the following excipient types will be discussed: surface active agents, preservatives, polymer choice and skin penetration enhancers.

Considerations include the …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

October 18 – Injection Devices
October 25 – Transdermal/Topical Delivery